These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26410305)

  • 1. DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3/Twist1/P-glycoprotein signaling.
    Wu K; Wang B; Chen Y; Zhou J; Huang J; Hui K; Zeng J; Zhu J; Zhang K; Li L; Guo P; Wang X; Hsieh JT; He D; Fan J
    Cell Signal; 2015 Dec; 27(12):2515-23. PubMed ID: 26410305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twist confers chemoresistance to anthracyclines in bladder cancer through upregulating P-glycoprotein.
    Chen Y; Li L; Zeng J; Wu K; Zhou J; Guo P; Zhang D; Xue Y; Liang L; Wang X; Chang LS; He D
    Chemotherapy; 2012; 58(4):264-72. PubMed ID: 22986993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mechanism of intravesical instillation of pirarubicin for preventing recurrence of non-muscle invasive bladder cancer].
    Li Q; Xu T; Wang XF
    Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):904-7. PubMed ID: 20193328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NOS3 895G>T and CBR3 730G>A Are Associated with Recurrence Risk in Non-Muscle-Invasive Bladder Cancer with Intravesical Instillations of THP.
    Zhou Q; Ding W; Weng Y; Ding G; Xia G; Xu J; Xu K; Ding Q
    Chemotherapy; 2018; 63(4):191-197. PubMed ID: 30125887
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twist1 and Y-box-binding protein-1 are potential prognostic factors in bladder cancer.
    Song YH; Shiota M; Yokomizo A; Uchiumi T; Kiyoshima K; Kuroiwa K; Oda Y; Naito S
    Urol Oncol; 2014 Jan; 32(1):31.e1-7. PubMed ID: 23395237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epithelial-mesenchymal transition induced by GRO-α-CXCR2 promotes bladder cancer recurrence after intravesical chemotherapy.
    Chen L; Pan XW; Huang H; Gao Y; Yang QW; Wang LH; Cui XG; Xu DF
    Oncotarget; 2017 Jul; 8(28):45274-45285. PubMed ID: 28423359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Efficacy of European Organization for Research and Treatment of Cancer (EORTC) risk tables for the prediction of recurrence and progression of non-muscle invasive bladder cancer after intravesical pirarubicin instillation].
    Xu C; Jiang XZ; Zhang NZ; Ma L; Xu ZS
    Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):609-12. PubMed ID: 23158996
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metformin can block precancerous progression to invasive tumors of bladder through inhibiting STAT3-mediated signaling pathways.
    Pan Q; Yang GL; Yang JH; Lin SL; Liu N; Liu SS; Liu MY; Zhang LH; Huang YR; Shen RL; Liu Q; Gao JX; Bo JJ
    J Exp Clin Cancer Res; 2015 Aug; 34(1):77. PubMed ID: 26245871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Downregulation of DAB2IP results in cell proliferation and invasion and contributes to unfavorable outcomes in bladder cancer.
    Shen YJ; Kong ZL; Wan FN; Wang HK; Bian XJ; Gan HL; Wang CF; Ye DW
    Cancer Sci; 2014 Jun; 105(6):704-12. PubMed ID: 24684735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis.
    Zhou J; Ning Z; Wang B; Yun EJ; Zhang T; Pong RC; Fazli L; Gleave M; Zeng J; Fan J; Wang X; Li L; Hsieh JT; He D; Wu K
    Cell Death Dis; 2015 Oct; 6(10):e1955. PubMed ID: 26512963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and Validation of Nitroxoline as a Novel STAT3 Inhibitor in Drug-resistant Urothelial Bladder Cancer.
    Lin W; Sun J; Sadahira T; Xu N; Wada K; Liu C; Araki M; Xu A; Watanabe M; Nasu Y; Huang P
    Int J Biol Sci; 2021; 17(12):3255-3267. PubMed ID: 34421363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Su Fu'ning Lotion's Inhibitory Effects on Bladder Cancer Cells In Vitro and In Vivo by Intravesical Instillation.
    Ren L; Yang X; Zhao L; Zhang H; Wang J
    Integr Cancer Ther; 2016 Mar; 15(1):80-6. PubMed ID: 26315609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Foxo3a suppression of urothelial cancer invasiveness through Twist1, Y-box-binding protein 1, and E-cadherin regulation.
    Shiota M; Song Y; Yokomizo A; Kiyoshima K; Tada Y; Uchino H; Uchiumi T; Inokuchi J; Oda Y; Kuroiwa K; Tatsugami K; Naito S
    Clin Cancer Res; 2010 Dec; 16(23):5654-63. PubMed ID: 21138866
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of PKM2 enhances anticancer efficiency of THP on bladder cancer.
    Su Q; Tao T; Tang L; Deng J; Darko KO; Zhou S; Peng M; He S; Zeng Q; Chen AF; Yang X
    J Cell Mol Med; 2018 May; 22(5):2774-2790. PubMed ID: 29512924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Knock-down of DAB2 interacting protein (DAB2IP) promotes proliferation and inhibits apoptosis of bladder cancer cells].
    Zhang K; Wang W; Wu K; Ding C; Zhu J; DU Y; Guan Z; Wang X; Fan J
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 May; 33(5):668-676. PubMed ID: 28502307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective randomized phase II trial of a single early intravesical instillation of pirarubicin (THP) in the prevention of bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma: the THP Monotherapy Study Group Trial.
    Ito A; Shintaku I; Satoh M; Ioritani N; Aizawa M; Tochigi T; Kawamura S; Aoki H; Numata I; Takeda A; Namiki S; Namima T; Ikeda Y; Kambe K; Kyan A; Ueno S; Orikasa K; Katoh S; Adachi H; Tokuyama S; Ishidoya S; Yamaguchi T; Arai Y
    J Clin Oncol; 2013 Apr; 31(11):1422-7. PubMed ID: 23460707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of cell cycle-associated proteins in non-muscle-invasive bladder cancer: correlation with intravesical recurrence following transurethral resection.
    Behnsawy HM; Miyake H; Abdalla MA; Sayed MA; Ahmed Ael-F; Fujisawa M
    Urol Oncol; 2011; 29(5):495-501. PubMed ID: 19914103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twist1 and Y-box-binding protein-1 promote malignant potential in bladder cancer cells.
    Shiota M; Yokomizo A; Itsumi M; Uchiumi T; Tada Y; Song Y; Kashiwagi E; Masubuchi D; Naito S
    BJU Int; 2011 Jul; 108(2 Pt 2):E142-9. PubMed ID: 21083641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A ROS/STAT3/HIF-1α signaling cascade mediates EGF-induced TWIST1 expression and prostate cancer cell invasion.
    Cho KH; Choi MJ; Jeong KJ; Kim JJ; Hwang MH; Shin SC; Park CG; Lee HY
    Prostate; 2014 May; 74(5):528-36. PubMed ID: 24435707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.